Hims & Hers, a tele-health start-up, aims to stand apart from dozens of Super Bowl commercials hawking snacks with a spot ...

Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

Let’s cut to the chase: erectile dysfunction (ED) is a common issue, but it’s not the end of the world. Not even on Valentine ...

A Super Bowl ad for weight loss medications from telehealth company Hims & Hers is optimized to engage and infuriate ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

For its most recently reported quarter (Q3 of 2024), Hims & Hers generated $401.6 million in revenue. That resulted in a free ...

The Super Bowl spot is part of a larger campaign as Hims & Hers continues to highlight its weight loss treatments. The ad ...

Investors in Hims & Hers Health Inc (Symbol: HIMS) saw new options begin trading today, for the March 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Hims & Hers Health, Inc. (HIMS) closed at $29.72 in the latest trading session, marking a -0.3% move from the prior day. This move lagged the S&P 500's daily gain of 0.61%. Elsewhere, the Dow ...